Artificial Endometrial Preparation for Frozen-Thawed Embryo Transfer with or without Pretreatment with Depot Gonadotropin Releasing Hormone Agonist in Women with Regular Menses.
Azimi Nekoo، Elham نويسنده Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran , , Chamani، Maryam نويسنده Tehran University of Medical Sciences, Tehran, Iran. Chamani, Maryam , Shahrokh Tehrani، Ensieh نويسنده Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran. Shahrokh Tehrani, Ensieh , Hossein Rashidi، Batool نويسنده Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran. Hossein Rashidi, Batool , Davari Tanha، Fatemeh نويسنده Department of Obstetrics and Gynecology, Tehran University of Medical Sciences, Tehran, Iran , , Kalantari، Vahid نويسنده St Maarten School of Medicine, American University of Integrative Sciences, Cole Bay, St. Maarten. Kalantari, Vahid
Objective: To investigate the reproductive outcome of artificial endometrial preparation with exogenous steroids for frozen-thawed embryo transfer with and without pre-treatment with depot gonadotropin releasing hormone agonist (GnRH-a) in women with regular menses.
AMaterials and methods:This is a prospective randomized clinical trial conducted in two RT centers on 176 women undergoing frozen-thawed embryo transfer. All patients received oral estradiol valerate 4 mg daily from day 2 to day 5 and 6 mg per day from day 6 to the day of the pregnancy test. In day 13 of cycle, an ultrasound examination was performed. After ultrasound confirmation of endometrial thickness (≥8 mm) and no ovarian activity, progesterone in cyclogest supp (800 mg daily) was added. The dose of estradiol would be increased to 8 mg per day if the endometrial thickness was less than 8mm. Two or 3 embryos were transferred via transcervical route 48 hours after the beginning of progesterone administration. In group A (93 patients), Difereline (3.75 mg Im), as a depot GnRH agonist was administered in the midluteal phase (day 21) of previous cycle. In the other group B (n = 83) steroid supplementation was commenced without prior pituitary suppression. Chemical and clinical pregnancy rates were compared in two groups.
Results:No significant differences were seen between two groups in terms of chemical pregnancy and clinical pregnancy rates.
Conclusion:The findings support the artificial protocol without any pretreatment suppressive drugs to reduce the adverse side effects of GnRH agonists also to minimize the costs.